Quarterly report · Q1
9987.TEDINET S100OZ8T
Period2022-04-01 → 2022-06-30
Filed2022-08-12
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥553.8bn | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Revenue | ¥2.24T | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥541.1bn | 2021-04-01 → 2021-06-30 | Cons. | Net sales |
| Operating income | ¥3.5bn | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Operating income | −¥1.6bn | 2021-04-01 → 2021-06-30 | Cons. | Operating income |
| Ordinary income | ¥4.6bn | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥23.4bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥443m | 2021-04-01 → 2021-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥4.5bn | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Profit before tax | −¥479m | 2021-04-01 → 2021-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.7bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥14.4bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥414m | 2021-04-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.7bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Net income | −¥373m | 2021-04-01 → 2021-06-30 | Cons. | Profit loss |
| Total assets | ¥1.17T | at 2022-06-30 | Cons. | Assets |
| Total assets | ¥1.14T | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥1.17T | at 2021-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥745.8bn | at 2022-06-30 | Cons. | Liabilities |
| Total liabilities | ¥723.7bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥419.3bn | at 2022-06-30 | Cons. | Net assets |
| Net assets / equity | ¥418.1bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥415.3bn | at 2021-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥132.1bn | at 2022-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥141.4bn | at 2022-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥30.49 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥163.19 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-4.66 | 2021-04-01 → 2021-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 36.0% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.4% | at 2021-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 40
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥52.6bn |
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥9.8bn |
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥42.8bn |
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥434m |
| jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥21.4bn |
| jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥21.4bn |
| jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥1m |
| jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥31m |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥533.5bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥519.6bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥13.8bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥2.4bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥11.5bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥2.9bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥8.6bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥587m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-06-30 | ¥618.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-06-30 | ¥553.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥65.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-06-30 | ¥3.5bn |
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥41.9bn |
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥9.8bn |
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥32.1bn |
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥644m |
| jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥21.9bn |
| jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥21.9bn |
| jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥5m |
| jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥323m |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥520.1bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥506.1bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥13.9bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | segment profit | 2021-04-01 → 2021-06-30 | −¥3.2bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥11.3bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥3.3bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥7.9bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥468m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-06-30 | ¥595.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-06-30 | ¥541.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥54.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-06-30 | −¥1.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 350
| Item | Context | Value | Unit |
|---|---|---|---|
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所（プライム市場）名古屋証券取引所（プレミア市場）札幌証券取引所 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)単元株式数は 100株であります。 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Voting rights (text) | FilingDateInstant | Text · Plus | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | Original text (Japanese)単元株式数は100株であります。 | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | Original text (Japanese)同上 | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)㈱スズケン | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)名古屋市東区東片端町８番地 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Notes changes in scope of consolidation or equity method (text) | CurrentYTDDuration | Text · Plus | |
| Notes changes in accounting policies in accordance with changes in accounting standards etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes changes in presentation quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes changes in accounting estimates quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes additional information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Description of fact that quarterly statement of cash flows has not been prepared (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Description of nature of differences between profit loss of reportable segments total and quarterly financial statements (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Description of nature of differences between profit loss of reportable segments total and quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |